- Stocks
- Healthcare
- NASDAQ: INO

Price (delayed)

$0.9625

Market cap

$250.38M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.17

Enterprise value

$236.12M

INOVIO is a biotechnology company focused on rapidly bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with HPV. INOVIO

INO's EPS is up by 20% since the previous quarter and by 19% year-on-year

INO's net income is up by 16% since the previous quarter and by 8% year-on-year

INO's quick ratio has dropped by 56% year-on-year and by 11% since the previous quarter

The equity has contracted by 44% YoY and by 17% from the previous quarter

What are the main financial stats of INO

Market
Valuations
Earnings

Shares outstanding

260.13M

Market cap

$250.38M

Enterprise value

$236.12M

Price to earnings (P/E)

N/A

Price to book (P/B)

1.08

Price to sales (P/S)

22.38

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

23.01

Revenue

$10.26M

EBIT

-$278.56M

EBITDA

-$273.07M

Free cash flow

-$217.18M

Per share
Balance sheet
Liquidity

EPS

-$1.17

Free cash flow per share

-$0.91

Book value per share

$0.89

Revenue per share

$0.04

TBVPS

$1.41

Total assets

$348.53M

Total liabilities

$126.17M

Debt

$32.07M

Equity

$222.36M

Working capital

$218.37M

Debt to equity

0.14

Current ratio

3.25

Quick ratio

2.73

Net debt/EBITDA

0.05

Margins
Efficiency
Dividend

EBITDA margin

-2,660.9%

Gross margin

100%

Net margin

-2,726.7%

Operating margin

-2,607.4%

Return on assets

-68%

Return on equity

-98%

Return on invested capital

-94.8%

Return on capital employed

-110.7%

Return on sales

-2,714.4%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Inovio Pharmaceuticals stock price performed over time

Intraday

1.73%

1 week

-11.7%

1 month

-24.8%

1 year

-74.4%

YTD

-38.3%

QTD

-38.3%

How have Inovio Pharmaceuticals's revenue and profit performed over time

Revenue

$10.26M

Gross profit

$10.26M

Operating income

-$267.57M

Net income

-$279.82M

Gross margin

100%

Net margin

-2,726.7%

The company's operating margin has surged by 85% YoY and by 10% QoQ

Inovio Pharmaceuticals's net margin has surged by 84% YoY and by 10% QoQ

INO's net income is up by 16% since the previous quarter and by 8% year-on-year

INO's operating income is up by 16% QoQ and by 11% YoY

What is Inovio Pharmaceuticals's growth rate over time

What is Inovio Pharmaceuticals stock price valuation

P/E

N/A

P/B

1.08

P/S

22.38

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

23.01

INO's EPS is up by 20% since the previous quarter and by 19% year-on-year

The stock's price to book (P/B) is 88% less than its 5-year quarterly average of 9.3 and 36% less than its last 4 quarters average of 1.7

The equity has contracted by 44% YoY and by 17% from the previous quarter

The P/S is 92% lower than the 5-year quarterly average of 268.0 and 88% lower than the last 4 quarters average of 189.6

INO's revenue is down by 7% since the previous quarter

How efficient is Inovio Pharmaceuticals business performance

INO's return on sales has surged by 84% year-on-year and by 10% since the previous quarter

INO's ROE has plunged by 57% YoY but it is up by 2.8% from the previous quarter

The company's return on invested capital fell by 47% YoY but it rose by 4.8% QoQ

INO's return on assets is down by 28% year-on-year but it is up by 8% since the previous quarter

What is INO's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for INO.

How did Inovio Pharmaceuticals financials performed over time

The total assets is 176% greater than the total liabilities

INO's quick ratio has dropped by 56% year-on-year and by 11% since the previous quarter

INO's current ratio has shrunk by 52% YoY and by 12% QoQ

Inovio Pharmaceuticals's debt is 86% lower than its equity

The debt to equity has soared by 75% YoY and by 17% from the previous quarter

The equity has contracted by 44% YoY and by 17% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.